A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Jazz Pharmaceuticals PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 30,600 shares of JAZZ stock, worth $3.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,600
Previous 36,200 15.47%
Holding current value
$3.79 Million
Previous $3.86 Million 11.73%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$100.57 - $116.37 $66.9 Million - $77.4 Million
664,822 Added 171.04%
1,053,521 $117 Million
Q2 2024

Aug 14, 2024

BUY
$103.94 - $118.98 $39.3 Million - $45 Million
378,042 Added 3547.36%
388,699 $41.5 Million
Q1 2024

May 15, 2024

SELL
$115.19 - $132.77 $2.26 Million - $2.6 Million
-19,609 Reduced 64.79%
10,657 $1.28 Million
Q4 2023

Feb 14, 2024

BUY
$114.26 - $136.0 $1.75 Million - $2.08 Million
15,282 Added 101.99%
30,266 $3.72 Million
Q3 2023

Nov 14, 2023

SELL
$122.0 - $145.31 $10.7 Million - $12.8 Million
-87,816 Reduced 85.42%
14,984 $1.94 Million
Q2 2023

Aug 14, 2023

SELL
$122.5 - $147.16 $20.8 Million - $25 Million
-169,769 Reduced 62.28%
102,800 $12.7 Million
Q1 2023

May 15, 2023

SELL
$133.98 - $160.47 $47.7 Million - $57.1 Million
-355,919 Reduced 56.63%
272,569 $39.9 Million
Q4 2022

Feb 14, 2023

BUY
$129.72 - $159.85 $81.5 Million - $100 Million
628,488 New
628,488 $100 Million
Q2 2022

Aug 15, 2022

BUY
$141.59 - $168.66 $25.1 Million - $29.8 Million
176,935 Added 33.37%
707,226 $110 Million
Q1 2022

May 16, 2022

BUY
$129.64 - $160.7 $57.5 Million - $71.3 Million
443,622 Added 511.86%
530,291 $82.6 Million
Q4 2021

Feb 14, 2022

BUY
$119.87 - $145.67 $4.7 Million - $5.71 Million
39,229 Added 82.69%
86,669 $11 Million
Q3 2021

Nov 15, 2021

SELL
$128.64 - $184.79 $118 Million - $169 Million
-915,032 Reduced 95.07%
47,440 $6.18 Million
Q2 2021

Aug 16, 2021

SELL
$160.2 - $186.42 $61.5 Million - $71.6 Million
-384,050 Reduced 28.52%
962,472 $171 Million
Q1 2021

May 17, 2021

BUY
$150.19 - $173.5 $59.5 Million - $68.8 Million
396,471 Added 41.73%
1,346,522 $221 Million
Q4 2020

Feb 16, 2021

BUY
$140.71 - $165.05 $12.8 Million - $15.1 Million
91,247 Added 10.62%
950,051 $157 Million
Q3 2020

Nov 16, 2020

SELL
$105.46 - $144.13 $56.9 Million - $77.8 Million
-539,960 Reduced 38.6%
858,804 $122 Million
Q2 2020

Aug 14, 2020

BUY
$95.68 - $121.88 $123 Million - $157 Million
1,286,792 Added 1149.21%
1,398,764 $154 Million
Q1 2020

May 15, 2020

BUY
$87.74 - $152.74 $65,892 - $114,707
751 Added 0.68%
111,972 $11.2 Million
Q4 2019

Feb 14, 2020

SELL
$117.65 - $153.73 $19.1 Million - $24.9 Million
-162,055 Reduced 59.3%
111,221 $16.6 Million
Q3 2019

Nov 14, 2019

BUY
$125.18 - $143.24 $13.9 Million - $15.9 Million
111,184 Added 68.59%
273,276 $35 Million
Q2 2019

Aug 14, 2019

SELL
$125.55 - $144.48 $7.69 Million - $8.85 Million
-61,255 Reduced 27.43%
162,092 $23.1 Million
Q1 2019

May 15, 2019

BUY
$121.81 - $142.95 $10.7 Million - $12.6 Million
88,236 Added 65.31%
223,347 $0
Q4 2018

Feb 14, 2019

BUY
$115.94 - $166.74 $11 Million - $15.8 Million
94,519 Added 232.85%
135,111 $16.7 Million
Q3 2018

Nov 13, 2018

BUY
$161.01 - $180.57 $4.78 Million - $5.36 Million
29,707 Added 272.92%
40,592 $0
Q2 2018

Aug 10, 2018

SELL
$146.33 - $183.18 $7.32 Million - $9.16 Million
-50,010 Reduced 82.12%
10,885 $0
Q1 2018

May 11, 2018

SELL
$135.59 - $157.16 $5.53 Million - $6.41 Million
-40,797 Reduced 40.12%
60,895 $9.2 Million
Q4 2017

Feb 09, 2018

SELL
$131.06 - $150.39 $72 Million - $82.6 Million
-549,231 Reduced 84.38%
101,692 $13.7 Million
Q3 2017

Nov 09, 2017

BUY
$142.62 - $155.6 $92.8 Million - $101 Million
650,923
650,923 $95.2 Million

Others Institutions Holding JAZZ

About Jazz Pharmaceuticals plc


  • Ticker JAZZ
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,680,700
  • Market Cap $7.76B
  • Description
  • Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement ...
More about JAZZ
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.